Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8466494 | 0.90 | AKR1B1 (0.49) | AKR1B1KMT2AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL9163294 | 0.87 | AKR1B1 (0.47) | AKR1B1KMT2AMEN1P2RX4GAA | |
| SCHEMBL8467038 | 0.87 | ALDH1A1 (0.52) | AKR1B1KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7223364 | 0.84 | POLB (0.45) | AKR1B1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL7230766 | 0.82 | POLB (0.42) | AKR1B1KMT2AMEN1SMN1; SMN2GAA | |
| SCHEMBL9362660 | 0.81 | AKR1B1 (0.38) | AKR1B1KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7225323 | 0.80 | HDAC3 (0.42) | KMT2AMEN1L3MBTL1TDP1GAA | |
| SCHEMBL7223994 | 0.80 | POLB (0.36) | AKR1B1KMT2AMEN1RAB9AGAA | |
| SCHEMBL7228473 | 0.80 | MAPT (0.40) | KMT2AMEN1NPC1SMN1; SMN2RAB9A | |
| SCHEMBL9353090 | 0.80 | KMT2A (0.52) | KMT2AMEN1NPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092566-A1 | Treatment of cancer with aldose reductase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | claimed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20100016404-A1 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2010-01-21 | — | — | US | claimed |
| EP-2032145-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | claimed |
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-16 | — | — | US | claimed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-5270342-A | Acetamide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | claimed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12090142-B2 | Combination therapy for the treatment of cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023220930-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS CROSS-REFERENCES TO RELATED APPLICATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-5430060-A | Aldose reductase inhibitor | ZENECA LIMITED (GB) | 1995-07-04 | — | — | US | disclosed |
| EP-0469887-B1 | Acetamide derivatives | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| WO-1994007867-A1 | SUBSTITUTED PYRIMIDINES FOR CONTROL OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058310-A1 | Remedies for vertebral canal stenosis | ALDOA, AKR1B1, AKR1A1 | AKR1B1 2/4885KMT2A 1229/4885MEN1 3165/4885 |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | AKR1B1 506/4885KMT2A 2591/4885MEN1 3081/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1B1 5/4885KMT2A 4011/4885MEN1 1642/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | AKR1B1 5/4885KMT2A 4011/4885MEN1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.